The Story Behind Our Mesenchymal Stem Cells ExoQure MSCs derived from Wharton’s Jelly in human umbilical cords exhibit superior proliferation and differentiation potential.
The results of thousands of global research projects and clinical trials conducted using MSCs (for the potential treatment of a wide variety of diseases and conditions) has radically increased the interest of physicians in the fast growing field of Regenerative Medicine. The experimental treatment of everything from diabetes to cancer to COVID-19 have benefited enormously from the regenerative properties of stem cells.
In recent years the use of Mesenchymal Stem Cells, or MSCs, has become widely viewed as the gold standard for stem cell therapy, holding promise as both a care option for disease and a therapeutic agent in regenerative medicine.
Research studies show once injected, MSCs can differentiate into a wide range of specialized cells. They have the potential to develop into mature cells that produce fat, cartilage, bone, tendons, and muscle.
In the research and clinical trial setting, MSCs have exhibited remarkable immune and anti-inflammatory properties, avoiding Graft-versus-Host disease and other potential issues that come from using stem cells from a donor.
Because MSCs can differentiate - both in the lab and in a patient’s body - and secrete a wide variety of important proteins and growth factors, MSCs can be used to induce a patient’s own body to regenerate tissue, while protecting it from stress-induced cell death and modulating inflammation.
MSCs are being studied for degenerative conditions such as Alzheimer’s, ALS and Parkinson’s, autoimmune diseases: rheumatoid arthritis, lupus, Muscular Dystrophy (MD) and Multiple Sclerosis (MS) as well as diabetes, and vascular conditions similarly stroke in addition to heart disease.
These properties, in combination with their developmental plasticity, have generated tremendous interest because of the potential use of MSC in regenerative medicine.